Association of Systemic Inflammation Level on Admission with Total and Cardiovascular‐Specific Death in Heart Failure with Preserved Ejection Fraction: A Large Multi‐Center Retrospective Longitudinal Study
Wenguang Lai,Xiaoli Zhao,Zhiyong Gao,Haozhang Huang,Donghui Huang,Yang Zhou,Guoxiao Liang,Shiqun Chen,Jin Liu,Yong Liu
DOI: https://doi.org/10.2147/jir.s462848
IF: 4.5
2024-08-21
Journal of Inflammation Research
Abstract:Wenguang Lai, 1, &ast Xiaoli Zhao, 2, &ast Zhiyong Gao, 1 Haozhang Huang, 3, 4 Donghui Huang, 1 Yang Zhou, 3, 4 Guoxiao Liang, 3, 4 Shiqun Chen, 3, 4 Jin Liu, 3 Yong Liu 3 1 Department of Pharmacy, Heyuan People's Hospital; Guangdong Provincial People's Hospital, Heyuan Hospital, Heyuan, 517001, People's Republic of China; 2 Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 611731, People's Republic of China; 3 Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, People's Republic of China; 4 Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yong Liu; Jin Liu, Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, People's Republic of China, Tel +86 02083827812-10528, Fax +86 02083851483, Email ; Purpose: Heart failure with preserved ejection fraction (HFpEF) is inherently a complex inflammatory syndrome, and heightened inflammation is strongly associated with an increased risk of death. However, the association of systemic inflammation levels with total and cardiovascular death among patients with HFpEF remains unknown. We aimed to investigate the prognostic impact of systemic inflammation on all-cause and cardiovascular death among patients with HFpEF. Patients and Methods: Patients with HFpEF were included in this study. Systemic inflammation response index (SIRI) is defined as the multiplication of neutrophil and monocyte divided by lymphocyte count, and patients were divided into four groups based on SIRI quartiles. Cox regression models and competing risk models were used to examine the relationships between SIRI and total and cardiovascular‐specific mortality, respectively. Results: 9,986 patients with HFpEF were included in five tertiary hospitals. During a median follow-up period of 4.4 years, a total of 2004 patients died, of which 965 were cardiovascular deaths. After fully adjusting for confounders, elevated SIRI level was significantly related to the increased risk of all-cause death (Q2, Q3, Q4: adjusted hazard ratio (aHR) [95 confidence interval (CI)%] =1.17[1.01– 1.35], 1.31[1.13– 1.52], 1.51[1.30– 1.76], respectively; P for trend < 0.001). The elevated quartile of SIRI showed higher risks of cardiovascular death, but there was no statistically significant increased risk of cardiovascular death across the lower SIRI quartile (model 3: Q2, Q3, Q4: aHR [95CI%] =1.22[0.99– 1.51], 1.50[1.20– 1.86], 1.73[1.37– 2.18], respectively; P for trend < 0.001). Conclusion: Elevated systemic inflammation level on admission was correlated with an increased risk of all-cause and cardiovascular death among patients with HFpEF. The SIRI may serve as a promising marker of risk stratification for patients with HFpEF. Keywords: heart failure with preserved ejection fraction, systemic inflammatory response index, all-cause death, cardiovascular death Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common form of HF in the older population, and the prevalence has been more than 50% of HF cases in the community, and the five-year mortality rate is more than 50%. 1,2 However, few currently available treatment strategies have shown clinical benefit in HFpEF. 3 Accordingly, early identification of at-risk patients with HFpEF is significant for clinicians. The long-term prognostic model based on traditional risk factors showed limited discrimination for predicting long-term mortality, and promising tools for risk stratification still need to be developed. 4 HFpEF is a complex clinical syndrome mediated by a complex mechanism, of which, elevated inflammation may contribute to the progression of disease. 5 The chronic inflammatory state can predispose to adverse cardiac remodeling such as left ventricular hypertrophy that can eventually lead to HFpEF. 6 Moreover, proinflammatory cytokines may contribute to endothelial dysfunction and reduced vascular compliance and subsequent concentric LV remodeling, reduced left ventricular compliance. 7 Together, these mechanisms can signific -Abstract Truncated-
immunology